Table 2.
Patient characteristics overall and by biomarker testing status
| Had ≥ 1 biomarker test (N = 764) | No biomarker test (N = 267) | Overall (N = 1031) | p value | |
|---|---|---|---|---|
| Age at diagnosis, years | 0.952 | |||
| Mean (SD) | 69.4 (9.48) | 69.4 (8.91) | 69.4 (9.33) | |
| Median [Q1, Q3] | 70.0 [63.0, 76.0] | 69.0 [63.0, 76.0] | 70.0 [63.0, 76.0] | |
| Age group at diagnosis, years, n (%) | 0.962 | |||
| 18–44 | 6 (0.8) | 1 (0.4) | 7 (0.7) | |
| 45–64 | 218 (28.5) | 75 (28.1) | 293 (28.4) | |
| 65–74 | 300 (39.3) | 106 (39.7) | 406 (39.4) | |
| 75–84 | 200 (26.2) | 72 (27.0) | 272 (26.4) | |
| 85+ | 40 (5.2) | 13 (4.9) | 53 (5.1) | |
| Sex, n (%) | 0.026 | |||
| Female | 420 (55.0) | 125 (46.8) | 545 (52.9) | |
| Male | 344 (45.0) | 142 (53.2) | 486 (47.1) | |
| Race, n (%) | 0.459 | |||
| Asian | 16 (2.1) | 3 (1.1) | 19 (1.8) | |
| Black or African American | 26 (3.4) | 8 (3.0) | 34 (3.3) | |
| Other race | 19 (2.5) | 11 (4.1) | 30 (2.9) | |
| Patient declined | 2 (0.3) | 0 (0.0) | 2 (0.2) | |
| White | 701 (91.8) | 245 (91.8) | 946 (91.8) | |
| Ethnicity, n (%) | 0.011 | |||
| Hispanic or Latino | 327 (42.8) | 90 (33.7) | 417 (40.4) | |
| Not Hispanic or Latino | 437 (57.2) | 177 (66.3) | 614 (59.6) | |
| Tobacco history, n (%) | 0.017 | |||
| No | 124 (16.2) | 25 (9.4) | 149 (14.5) | |
| Yes | 618 (80.9) | 221 (82.8) | 839 (81.4) | |
| Missing | 22 (2.9) | 21 (7.9) | 43 (4.2) | |
| Cancer history, n (%) | 0.821 | |||
| No | 588 (77.0) | 203 (76.0) | 791 (76.7) | |
| Yes | 176 (23.0) | 64 (24.0) | 240 (23.3) | |
| Cancer stage, n (%) | 0.497 | |||
| 0–IA | 221 (28.9) | 89 (33.3) | 310 (30.1) | |
| IB | 124 (16.2) | 38 (14.2) | 162 (15.7) | |
| II | 161 (21.1) | 58 (21.7) | 219 (21.2) | |
| III | 258 (33.8) | 82 (30.7) | 340 (33.0) | |
| ECOG performance status grade, n (%) | 0.210 | |||
| 0 | 309 (40.4) | 100 (37.5) | 409 (39.7) | |
| 1 | 196 (25.7) | 71 (26.6) | 267 (25.9) | |
| 2 | 30 (3.9) | 14 (5.2) | 44 (4.3) | |
| 3 | 7 (0.9) | 7 (2.6) | 14 (1.4) | |
| 4 | 1 (0.1) | 0 (0.0) | 1 (0.1) | |
| Missing | 221 (28.9) | 75 (28.1) | 296 (28.7) | |
| Diagnosis method, n (%) | 0.006 | |||
| Biopsy | 342 (44.8) | 132 (49.4) | 474 (46.0) | |
| Clinicala | 2 (0.3) | 2 (0.7) | 4 (0.4) | |
| Cytology | 9 (1.2) | 7 (2.6) | 16 (1.6) | |
| Fine needle aspirate | 57 (7.5) | 15 (5.6) | 72 (7.0) | |
| Other | 1 (0.1) | 3 (1.1) | 4 (0.4) | |
| Surgical resection | 351 (45.9) | 104 (39.0) | 455 (44.1) | |
| Unknown | 2 (0.3) | 4 (1.5) | 6 (0.6) | |
| Year of initial diagnosis, n (%) | < 0.001 | |||
| 2011 | 21 (2.7) | 17 (6.4) | 38 (3.7) | |
| 2012 | 27 (3.5) | 18 (6.7) | 45 (4.4) | |
| 2013 | 49 (6.4) | 19 (7.1) | 68 (6.6) | |
| 2014 | 55 (7.2) | 31 (11.6) | 86 (8.3) | |
| 2015 | 84 (11.0) | 51 (19.1) | 135 (13.1) | |
| 2016 | 79 (10.3) | 47 (17.6) | 126 (12.0) | |
| 2017 | 117 (15.3) | 29 (10.9) | 146 (14.2) | |
| 2018 | 127 (16.6) | 21 (7.9) | 148 (14.4) | |
| 2019 | 90 (11.8) | 23 (8.6) | 113 (11.0) | |
| 2020 | 78 (10.2) | 6 (2.2) | 84 (8.1) | |
| 2021 | 37 (4.8) | 5 (1.9) | 42 (4.1) |
Clinical suspicion of a patient with symptoms indicating eNSCLC
ECOG Eastern Cooperative Oncology Group, Q1 first quartile, Q3 third quartile, SD standard deviation